Author(s):
Pavan Kalyan Regeti, B. Sunitha, C. Parthiban, M. Sudhakar
Email(s):
kalyanpavan373@gmail.com
DOI:
10.52711/2231-5675.2024.00041 
Address:
Pavan Kalyan Regeti, B. Sunitha*, C. Parthiban, M. Sudhakar
Department of Pharmaceutical Analysis, Mallareddy College of Pharmacy, Marisammaguda, Secunderabad 500010, Telangana, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
A simple, Accurate, precise method was developed for the simultaneous estimation of the Dapagliflozin and Vildagliptin in tablet dosage form. Chromatogram was run through Discovery C18 (4.6 x 150mm, 5µm). Mobile phase containing Acetonitrile: Na2hpo4 taken in the ratio 70:30 was pumped through column at a flow rate of 0.8 ml/min. Buffer used in this method Phosphate buffer and ph is adjusted to 5.2 by adding 0.1% Formic acid. Temperature was maintained at 30°C. Optimized wavelength selected was 220nm. Retention time of Dapagliflozin and Vildagliptin were found to be 2.307min and 2.865min. %RSD of the Dapagliflozin and Vildagliptin were and found to be 0.9 and 0.7 respectively. %Recovery was obtained as 100.41% and 99.94% for Dapagliflozin and Vildagliptin respectively. LOD, LOQ values obtained from regression equations of Dapagliflozin and Vildagliptin were 0.02, 0.07 and 0.24, 0.72 respectively. Regression equation of Dapagliflozin is y = 42540x + 1488.4. And y = 38485x + 2186.5 of Vildagliptin. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.
Cite this article:
Pavan Kalyan Regeti, B. Sunitha, C. Parthiban, M. Sudhakar. Method Development and Validation for Simultaneous Estimation of Dapagliflozin and Vildagliptin in Pharmaceutical Dosage Form by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2024; 14(4):229-3. doi: 10.52711/2231-5675.2024.00041
Cite(Electronic):
Pavan Kalyan Regeti, B. Sunitha, C. Parthiban, M. Sudhakar. Method Development and Validation for Simultaneous Estimation of Dapagliflozin and Vildagliptin in Pharmaceutical Dosage Form by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2024; 14(4):229-3. doi: 10.52711/2231-5675.2024.00041 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-14-4-5
6. REFERENCES:
1. Samy M. El-Megharbel et.al. Synthesis and Spectroscopic Characterization of Dapagliflozin/Zn (II), Cr (III) and Se (IV) Novel Complexes That Ameliorate Hepatic Damage, Hyperglycemia and Oxidative Injury Induced by Streptozotocin-Induced Diabetic Male Rats and Their Antibacterial Activity Crystals. 2022; 12(3): 30.
2. Arintaya Phrommintikul et.al. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol. 2019 Jun; 85(6): 1337–1347.
3. Mahesh Attimarad et.al. Smart eco-friendly mathematically manipulated UV spectroscopic methods to resolve severely overlapped spectra of a binary mixture of dapagliflozin with sitagliptin and vildagliptin. Microchemical Journal. 2023; 190: 108700
4. Sen AK et.al. Various innovative UV spectroscopic methodologies for concurrent estimation of dapagliflozin and vildagliptin in combined tablet. J Appl Pharm Sci. 2023; 13(09): 213–223
5. Joshi A et.al. Bioequivalence study of a fixed-dose combination of Dapagliflozin/ Vildagliptin Sustained Release tablets in healthy adult male subjects: A Randomized, Open-Label, Crossover Study. Journal of Drug Delivery and Therapeutics. 2022; 12(6): 105-109
6. Summary of Product Characteristics: Galvus (vildagliptin) oral tablets.
7. Chaphekar et.al. Development and Validation of RP-HPLC Assay Method for Vildagliptin Using Qbd Approach and Its Application to Forced Degradation Studies. International Journal of Pharmaceutical Sciences and Drug Research. 2016; 8(3): 157-165
8. B. Sivagami et.al. A Highly Validated RP-HPLC Method Development for the Simultaneous Estimation of Dapagliflozin and Saxagliptin in Tablet Dosage Forms. International Journal of Pharmaceutical Sciences and Drug Research. 2018; 10(5): 372-378.
9. Gunasekar Manoharan et.al. Stability-Indicating RP-HPLC Method Development for Simultaneous Determination and Estimation of Dapagliflozin in Raw and Tablet Formulation. Chemistry Research Journal. 2018; 3(2): 159-164
10. Fahima Aktar et.al. Study of the Effects of Complexation of Lead with Metformin, Glimepiride, Vildagliptin and Dapagliflozin in Mice Model. Microbial Bioactives. 2020; 3(1): 125-133.
11. Gautam K, et al. Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized, Open-label Study. Cureus. 2023; 15(4): e38200. DOI 10.7759/cureus.38200
12. B. T. Sadhana, S. K. Mohite, M. Snehal, and R. Sucheta. Development and validation of UV Spectrophotometric methods for simultaneous estimation of Voglibose and Dapagliflozin hydrochloride in bulk and tablet dosage form. Indo Ame.J.Pharm.Res.2013; 3: 7018-7024.
13. P.M.Pallavi, R.D.Sonali, C.D. Praveen. Development and validation of UV derivative spectrophotometric methods for the determination of Glimepiride, Dapagliflozin hydrochloride and Pioglitazone hydrochloride in bulk and marketed formulation, J. Pharmaceut. Sci. Innov. 2012; 1: 58-62.
14. K. Mousumi and P. K. Choudary, HPLC method for estimation of Dapagliflozin hydrochloride in formulated microspheres and tablet dosage form, Indian J. Pharmaceut. Sci. 2009; 71: 318-320.
15. M. A. Saeed, S. Najma and M. Z. Hashim. Development and validation of RP HPLCmethod for the Analysis of Dapagliflozin, Pak. J. Pharm. Sci. 2006; 19: 231-235 231.
16. ICH, Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonization, IFPMA, Geneva, (1996)
17. IUPAC. Compendium of Chemical Terminology, 2nd edn. (The Gold Book). PAC69, 1137 (1997). Glossary of terms used in Computational Drug Design (IUPAC Recommendations.
18. Indian Pharmacopoeia, Indian Pharmacopoeial Commission, Controller of Publication, Government of India, Ministry of health and Family Welfare, Ghaziabad, India. 2010; 2: 1657-1658.